Cost-effectiveness of clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention:A systematic reviewOA
Clopidogrel is widely prescribed to individuals with acute coronary syndrome(ACS)treated using percutaneous coronary intervention(PCI).This systematic review aims to synthesize existing economic evidence of clopidogrel in patients with ACS undergoing PCI.Preferred Reporting Items for Systematic Reviews and Meta‑Analyses(PRISMA)guidelines were used to systematically review the literature with relevant keywords in the databases like PubMed,Cochrane,Scopus,Cost Effectiveness(CE)Analysis Registry,Health Technology Assessment(HTA)Database,Health Economic Evaluation Database(HEED),to identify studies on economic evaluation of clopidogrel in patients with ACS undergoing PCI from 1991 to 2024.This review included only full cost‑effectiveness(CE)analyses of clopidogrel compared to other antiplatelet drugs in patients with ACS undergoing PCI and excluded partial economic evaluations.Data were extracted from the shortlisted articles and summarized.Only seven studies fulfilled all inclusion criteria and were included in the qualitative synthesis.Of these,four primarily evaluated the economic impact of clopidogrel compared to prasugrel.The overall incremental cost‑effectiveness ratios(ICERs)ranged between−$272,230/quality‑adjusted life year(QALY)and$60,628/QALY.The wide variation in ICERs is explained by using different study designs,countries,cost assumptions,economic modelling approaches,and comparators and willingness‑to‑pay(WTP)thresholds,which may restrict the applicability of these findings in a broader population.Cost‑effectiveness of clopidogrel in ACS patients undergoing PCI is highly related to the comparator used in the analysis.Additional comprehensive evaluations using alternative comparators are necessary to ascertain the CE of clopidogrel.
Saba Abidi;Shridhar Dwivedi;Vinod Sharma;Anoop Kumar;Sushama Talegaonkar
School of Allied Health Sciences and Management,Delhi Pharmaceutical Sciences and Research University,New Delhi 110017,IndiaNational Heart Institute,New Delhi 110065,IndiaNational Heart Institute,New Delhi 110065,IndiaDepartment of Pharmacology,Delhi Pharmaceutical Sciences and Research University,New Delhi 110017,IndiaDepartment of Pharmaceutics,School of Pharmaceutical Sciences,Delhi Pharmaceutical Sciences and Research University,New Delhi 110017,India
医药卫生
Acute coronary syndromeAntiplateletClopidogrelCost‑effectivenessEconomic evaluationPercutaneous coronary interventionSystematic review
《Pharmacoeconomics and Policy》 2026 (1)
P.4-11,8
评论